久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Cyxone Inks API Deal with European CDMO contractpharma
    January 20, 2022
    Takes next step in multiple sclerosis program engaging CDMO for production of drug candidate T20K.
  • Cyxone appoints Henrik Hang as CFO firstwordpharma
    June 10, 2021
    Cyxone AB (publ) (“Cyxone or the Company”) has appointed Henrik Hang as new CFO as of August 1st, 2021. Henrik has a degree in business administration and substantial experience from many years as CFO for international companies listed on First North Grow
  • Cyxone Explores Orphan Drug Designation for Rabeximod americanpharmaceuticalreview
    September 09, 2019
    Cyxone announced the company's board of directors has decided to explore the possibilities of an orphan drug designation (ODD) of the drug candidate Rabeximod.
  • Cyxone Submits First Application to Start Rabeximod Clinical Trial americanpharmaceuticalreview
    July 08, 2019
    Cyxone has submitted an application to the Central Ethics Committee (CEC) in Poland for permission to start a clinical phase IIb trial with its drug candidate Rabeximod, which is in development for the treatment of rheumatoid arthritis (RA).
PharmaSources Customer Service